278 related articles for article (PubMed ID: 11090074)
1. A carboxy-terminal domain of ELL is required and sufficient for immortalization of myeloid progenitors by MLL-ELL.
DiMartino JF; Miller T; Ayton PM; Landewe T; Hess JL; Cleary ML; Shilatifard A
Blood; 2000 Dec; 96(12):3887-93. PubMed ID: 11090074
[TBL] [Abstract][Full Text] [Related]
2. The AF10 leucine zipper is required for leukemic transformation of myeloid progenitors by MLL-AF10.
DiMartino JF; Ayton PM; Chen EH; Naftzger CC; Young BD; Cleary ML
Blood; 2002 May; 99(10):3780-5. PubMed ID: 11986236
[TBL] [Abstract][Full Text] [Related]
3. Retrovirus-mediated gene transfer of MLL-ELL transforms primary myeloid progenitors and causes acute myeloid leukemias in mice.
Lavau C; Luo RT; Du C; Thirman MJ
Proc Natl Acad Sci U S A; 2000 Sep; 97(20):10984-9. PubMed ID: 10995463
[TBL] [Abstract][Full Text] [Related]
4. The elongation domain of ELL is dispensable but its ELL-associated factor 1 interaction domain is essential for MLL-ELL-induced leukemogenesis.
Luo RT; Lavau C; Du C; Simone F; Polak PE; Kawamata S; Thirman MJ
Mol Cell Biol; 2001 Aug; 21(16):5678-87. PubMed ID: 11463848
[TBL] [Abstract][Full Text] [Related]
5. ELL-associated factor 2 (EAF2), a functional homolog of EAF1 with alternative ELL binding properties.
Simone F; Luo RT; Polak PE; Kaberlein JJ; Thirman MJ
Blood; 2003 Mar; 101(6):2355-62. PubMed ID: 12446457
[TBL] [Abstract][Full Text] [Related]
6. EAF1, a novel ELL-associated factor that is delocalized by expression of the MLL-ELL fusion protein.
Simone F; Polak PE; Kaberlein JJ; Luo RT; Levitan DA; Thirman MJ
Blood; 2001 Jul; 98(1):201-9. PubMed ID: 11418481
[TBL] [Abstract][Full Text] [Related]
7. Cloning of ELL, a gene that fuses to MLL in a t(11;19)(q23;p13.1) in acute myeloid leukemia.
Thirman MJ; Levitan DA; Kobayashi H; Simon MC; Rowley JD
Proc Natl Acad Sci U S A; 1994 Dec; 91(25):12110-4. PubMed ID: 7991593
[TBL] [Abstract][Full Text] [Related]
8. Molecular analysis of t(11;19) breakpoints in childhood acute leukemias.
Rubnitz JE; Behm FG; Curcio-Brint AM; Pinheiro RP; Carroll AJ; Raimondi SC; Shurtleff SA; Downing JR
Blood; 1996 Jun; 87(11):4804-8. PubMed ID: 8639852
[TBL] [Abstract][Full Text] [Related]
9. Common mechanism for oncogenic activation of MLL by forkhead family proteins.
So CW; Cleary ML
Blood; 2003 Jan; 101(2):633-9. PubMed ID: 12393557
[TBL] [Abstract][Full Text] [Related]
10. Transcriptional inhibition of p53 by the MLL/MEN chimeric protein found in myeloid leukemia.
Maki K; Mitani K; Yamagata T; Kurokawa M; Kanda Y; Yazaki Y; Hirai H
Blood; 1999 May; 93(10):3216-24. PubMed ID: 10233872
[TBL] [Abstract][Full Text] [Related]
11. Physical interaction and functional antagonism between the RNA polymerase II elongation factor ELL and p53.
Shinobu N; Maeda T; Aso T; Ito T; Kondo T; Koike K; Hatakeyama M
J Biol Chem; 1999 Jun; 274(24):17003-10. PubMed ID: 10358050
[TBL] [Abstract][Full Text] [Related]
12. MLL-AFX requires the transcriptional effector domains of AFX to transform myeloid progenitors and transdominantly interfere with forkhead protein function.
So CW; Cleary ML
Mol Cell Biol; 2002 Sep; 22(18):6542-52. PubMed ID: 12192052
[TBL] [Abstract][Full Text] [Related]
13. Transformation of myeloid progenitors by MLL oncoproteins is dependent on Hoxa7 and Hoxa9.
Ayton PM; Cleary ML
Genes Dev; 2003 Sep; 17(18):2298-307. PubMed ID: 12952893
[TBL] [Abstract][Full Text] [Related]
14. The elongation factor ELL (eleven-nineteen lysine-rich leukemia) is a selective coregulator for steroid receptor functions.
Pascual-Le Tallec L; Simone F; Viengchareun S; Meduri G; Thirman MJ; Lombès M
Mol Endocrinol; 2005 May; 19(5):1158-69. PubMed ID: 15650021
[TBL] [Abstract][Full Text] [Related]
15. Structure and function of RNA polymerase II elongation factor ELL. Identification of two overlapping ELL functional domains that govern its interaction with polymerase and the ternary elongation complex.
Shilatifard A; Haque D; Conaway RC; Conaway JW
J Biol Chem; 1997 Aug; 272(35):22355-63. PubMed ID: 9268387
[TBL] [Abstract][Full Text] [Related]
16. The small oligomerization domain of gephyrin converts MLL to an oncogene.
Eguchi M; Eguchi-Ishimae M; Greaves M
Blood; 2004 May; 103(10):3876-82. PubMed ID: 14751928
[TBL] [Abstract][Full Text] [Related]
17. ELL and EAF1 are Cajal body components that are disrupted in MLL-ELL leukemia.
Polak PE; Simone F; Kaberlein JJ; Luo RT; Thirman MJ
Mol Biol Cell; 2003 Apr; 14(4):1517-28. PubMed ID: 12686606
[TBL] [Abstract][Full Text] [Related]
18. An RNA polymerase II elongation factor encoded by the human ELL gene.
Shilatifard A; Lane WS; Jackson KW; Conaway RC; Conaway JW
Science; 1996 Mar; 271(5257):1873-6. PubMed ID: 8596958
[TBL] [Abstract][Full Text] [Related]
19. Subcellular localization of the MEN, MLL/MEN and truncated MLL proteins expressed in leukemic cells carrying the t(11;19)(q23;p13.1) translocation.
Kanda Y; Mitani K; Tanaka T; Tanaka K; Ogawa S; Yazaki Y; Hirai H
Int J Hematol; 1997 Aug; 66(2):189-95. PubMed ID: 9277049
[TBL] [Abstract][Full Text] [Related]
20. Developmental analysis and subcellular localization of the murine homologue of ELL.
Thirman MJ; Diskin EB; Bin SS; Ip HS; Miller JM; Simon MC
Proc Natl Acad Sci U S A; 1997 Feb; 94(4):1408-13. PubMed ID: 9037066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
